Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
Yoshiyuki YamamotoMakoto IshiiAkihiro YoshimuraTakuji HayashiNorihiko KawamuraAkira NagaharaYasutomo NakaiMasashi NakayamaKen-Ichi KakimotoKazuo NishimuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Previous androgen receptor-axis-targeted therapy was the only risk factor for biochemical progression. Poor performance status, anemia, and high neutrophil-lymphocyte ratio were risk factors for poor prognosis in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. These risk factors seem useful for identifying patients with survival benefit from cabazitaxel treatment.